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Mycobacterium tuberculosis (MTB) and human immunodeﬁciency virus (HIV) coinfection remains a
global public health challenge. We report a 40 year old African American male who is a known HIV-
positive patient, non-compliant with his antiretrovirals and developed pulmonary tuberculosis. His
chief complaints were chronic cough, fever, night sweats and undocumented weight loss. He had a prior
positive T-SPOT-TB test; however, chest radiograph and sputum smear examination revealed normal
results. PCR-based GeneXPERT MTB/RIF assay was ordered and conﬁrmed MTB infection. The sputum
cultures grew MTB and sensitivities showed susceptibility to all primary anti-tuberculosis medications. A
delay in diagnosis and initiation of MTB therapy, in the setting of HIV or AIDS, may result in rapid disease
progression and worse clinical outcome.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mycobacterium tuberculosis (MTB) and human immunodeﬁ-
ciency virus (HIV) co-infection is one of the major public health
burdens globally. According to the World Health Organization
(WHO), nearly 15% of individuals diagnosed with MTB were HIV
positive and a total of 360,000 deaths were attributed to MTB-HIV
coinfection alone [1,2]. Clinical evidence suggests that MTB is the
most common opportunistic infection causing exacerbation of viral
load and diminished CD4 count in HIV patients. It also remains the
leading cause of death in patients with Acquired Immunodeﬁciency
Syndrome (AIDS) [2e4]. Reciprocally, by decreasing the body's cell
mediated immunity, HIV increases the risk of MTB progression and
reactivation of latent TB infection (LTBI) [5]. HIV coinfection can
alter the pathogenesis of MTB and lead to negative sputum smear
results, atypical radiographic manifestations and extrapulmonary
manifestations, which poses difﬁculty in diagnosing MTB disease
[6,7]. The synergistic repressive effect of MTB and HIV on the im-
mune system, drug interactions and their overlapping toxicities,
and the existence of a condition called immune reconstitution in-
ﬂammatory syndrome (IRIS) complicate the co-treatment of MTB
and HIV [8,9]. Here we report a patient previously diagnosed withealth, 4815 West Markham,
il).
Ltd. This is an open access article uHIV and a history of non-compliance with his anti-retroviral
medications, who subsequently developed MTB disease.
2. Case report
A forty-one year old African Americanmalewith a history of HIV
infection was arrested and sent to jail for his offense. He was pre-
viously diagnosed with HIV in 2005. He had a history of non-
compliance with his highly active antiretroviral therapy (HAART)
and was currently not on any medications. He was screened at the
correctional facility for complaints of fever, night sweats, cough and
undocumented weight loss for the past four weeks. The laboratory
studies demonstrated a white blood cell count of 3.73  103/mm3,
normal liver function proﬁle, CD4 count of 130/mm3 and viral load
of >500,000 copies/ml. The chest x-ray obtained was normal. The
patient's T-SPOT.TB (Oxford Immunotec Inc, Marlborough, MA; TST),
an Interferon Gamma Release Assay (IGRA) test, performed a year
ago, was positive. Unfortunately, no further evaluationwas done by
the primary physician at the time. The sputum collected during the
current work up was smear-negative, but the PCR-based analyses
with the GeneXPERT MTB/RIF assay detected M. tuberculosis in the
specimen and showed no rifampicin (RIF) resistance. The patient
was initiated on four drug anti-tuberculous therapy with isoniazid
(INH), rifampin (RIF), ethambutol (EMB) and pyrazinamide (PZA).
The sputum culture grew M. tuberculosis after four weeks of incu-
bation and sensitivities showed the organism to be susceptible to
all the aforementioned primary anti-tuberculous drugs.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The case report describes a known HIV-positive patient who
presented with signs and symptoms of active tuberculosis such as
chronic cough, fever, night sweats andweight loss of approximately
four weeks duration. However, his normal chest x-ray and smear-
negative sputum exam was misleading from the diagnostic view-
point. Clinical evidence has shown that the likelihood of mis-
diagnosing MTB is higher in patients infected with HIV [10]. The
diagnostic difﬁculty arises from non-speciﬁc symptoms, absence of
typical radiological presentations and sputum smears that are
negative for acid fast bacilli (AFB), which are more frequently
observed in HIV co-infected patients. Studies have shown that
radiographic presentations of MTB among HIV-infected patients
are either unremarkable or would appear as adenopathy rather
than lung consolidation/cavitation commonly seen in non HIV pa-
tients [11]. A lowCD4þ lymphocyte level has also been linked to the
atypical chest x-ray ﬁndings seen in MTB-HIV coinfections [12].
Down-regulation of the body's immune response to MTB infection
in HIV/AIDS compounded by high viral load is a potential reason for
the diagnostic dilemma [13]. A high index of suspicion should be
exercised in HIV infected patients with pneumonic presentations
because delayed initiation of anti-tuberculosis therapy, especially
in patients with advanced immunosuppression, may lead to MTB
progression, decreased survival and higher mortality rate. The
diagnosis of MTB is conﬁrmed by a combination of various factors
including clinical and radiological features, IGRA, Tuberculin skin
test (TST), AFB, culture and GeneXPERT MTB/RIF assay [14,15].
Utilization of newer laboratory methods is needed for timely
diagnosis in scenarios when a deﬁnitive diagnosis of MTB cannot be
formulated solely on clinical presentations. Growth based detection
of M. Tuberculosis in cultures and molecular techniques such as
Nucleic Acid Ampliﬁcation Testing (NAAT) are proven to be more
reliable in diagnosing MTB infection and determining drug resis-
tance based on their reproducibility and high speciﬁcity [16,17].
However, concerns on high cost, requirement of technical expertise
and strict quality control limit the use of the NAAT method. T-SPOT
TB test, an Interferon gamma release assay (IGRA), is a blood test
that measures immune reactivity to M. Tuberculosis. It must be
stressed that once a prior positive IGRA or TST test has been noted,
it should be rigorously followed-up [18]. However, IGRA tests
cannot delineate between latent TB infection and active disease.
The tests may also show both high false positives and false nega-
tives (conversion/reversion), especially in the settings of MTB-HIV
coinfections [19]. Here in belies the signiﬁcance of the diagnostic
capabilities of the recently introduced PCR-based GeneXPERT MTB/
RIF assay, including detection of smear-negative cases and extrap-
ulmonary tuberculosis, a frequent presentation in HIV-MTB coin-
fection [20,21]. GeneXPERT MTB/RIF assays have been
enthusiastically introduced in regions highly affected with MTB-
HIV coinfections, such as in South Africa [22,23]. The paucibacil-
lary nature of the disease, especially in HIV-MTB coinfections, poses
special problems. GeneXPERT MTB/RIF assay is considerably more
effective at detecting TB than sputum microscopy with no signiﬁ-
cant difference in performance by sex or HIV status [20,21].
Challenges in the co-management of MTB and HIV include cu-
mulative drug toxicities, potential drug interactions, pill burden
and complications such as IRIS and multi-drug resistant TB (MDR-
TB) [24]. WHO and Centers for Disease Control and Prevention
guidelines recommend the standard 6-month course of MTB ther-
apy consisting of INH, RIF, EMB and PZA regardless of HIV status.
However, in HIV infected individuals with CD4 count of <200 mm3,
the guidelines strongly suggest starting HAART between 2 and 8
weeks after initiation of anti-TB medications [25]. IRIS may develop
in MTB and HIV co-infected patients who are treated with anti-TBmedications concomitantly with HAART [26]. This risk is esti-
mated to occur in 11%e45% of patients co-infected with TB and HIV,
and is enhanced with early institution of therapy, as circulating
CD4s cause exaggerated response to the macrophage-restricted
M. tuberculosis [27]. Predictors of IRIS include CD4 count
<50 cells/mm3; higher on-antiretroviral therapy (ART) CD4 counts;
high pre-ART and lower on-ART HIV viral loads; severity of TB
disease, especially high pathogen burden; and less than 30-day
interval between initiation of TB and HIV treatments. However, the
strong emphasis is not to delay treatment for either illness [28]. On
the other hand, inadequate initial treatment may lead to the pos-
sibility of development of MDR-TB, though the current prevalence
is low. MDR-TB remains a concern not only because of its longer
duration and complex treatment, but also because of its associated
increased transmission risk among contacts and increased mor-
tality rates in HIV co-infected patients [29].
4. Conclusion
In summary, challenges in the diagnosis and treatment of MTB-
HIV coinfection include accuracy of standard diagnostic techniques
which may be often reported as false-negative, challenges of pol-
ypharmacy including drug compliance, potential drug interactions
and toxicities. Other complications such as IRIS may sometimes
pose diagnostic challenges and affect management outcomes. In
most cases, simultaneous treatment of MTB and HIV is preferred
over a delay in therapy for both diseases. Moreover, the require-
ment for improved diagnostic methods like GeneXPERT MTB/RIF
assay and aggressive MTB case detections in high risk populations
especially individuals diagnosed with HIV/AIDS cannot be
overemphasized.
Disclaimer
This case scenario was used in a previous review article to
elucidate the importance of GeneXpertMTB/RIF assay. (Patil N, Saba
H, Marco A, Samant R, Mukasa L. 2014. Initial experience with
GeneXpertMTB/RIF assay in the Arkansas tuberculosis control
program. Australas Med J. 7(5):203e207.)
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